Monte Alto

Monte Alto Bio (later known as Morpheus Bio) is a Seattle-based biotechnology company focused on the development of next-generation oncology therapeutics, particularly antibody-drug conjugates (ADCs). The company was established by Dr. Clay Siegall, a prominent figure in the biotech industry known for his leadership at Seagen. Monte Alto Bio leverages advanced protein engineering platforms to identify and validate novel tumor targets with the goal of creating therapies with superior therapeutic indices. In 2023, the company's assets and leadership team were integrated into Immunome following a strategic transaction that saw Dr. Siegall become the CEO of the combined entity. The company's pipeline includes several pre-clinical programs targeting high unmet needs in solid tumors and hematologic malignancies. This integration has positioned the technology within a publicly traded platform to accelerate the development of its innovative oncology candidates.